On “Current Role of Antithrombotic Agents in the Treatment of Acute Coronary Syndromes” (Semin Thromb Hemost 2004;30:627-632)

Semin Thromb Hemost 2005; 31(2): 248
DOI: 10.1055/s-2005-869530

LETTER TO THE EDITOR

Christopher O. Nessel¹

¹Executive Director, Clinical Development, The Medicines Company, Parsippany, New Jersey

1 Assessment of the Safety and Efficacy of a New Thrombolytic Regiment (ASSENT)-3 Investigators . Efficacy and safety of tenecteplase in combination with enoxaparin, abeiximab, or unfractionated heparin. The ASSENT-3 randomised trial in acute myocardial infarction. Lancet. 2001; 35 605-613

Christopher O NesselM.D.

Executive Director, Clinical Development, The Medicines Company

8 Campus Drive, Parsippany, NJ 07054